Kutluk Oktay, M.D., FACOG
Professor of Obstetrics & Gynecology, Medicine, and Cell Biology & Anatomy, Director, Division of Reproductive Medicine & Institute for Fertility Preservation
Department of Obstetrics & Gynecology
Munger Pavillion, Rm# 617
Valhalla, NY 10595
Please visit www.fertilitypreservation.org
Kutluk Oktay, MD, FACOG is one of the world's foremost experts in fertility preservation as well as ovarian stimulation and in vitro fertilization for infertility treatments. He developed and performed the world's first ovarian transplantation procedures as well as pioneered new ovarian stimulation protocols for embryo and oocyte freezing for breast and endometrial cancer patients. Dr. Oktay conducted key research on ovarian follicle and embryo development, as well as on controlled ovarian stimulation and in vitro fertilization.
Dr. Oktay has devoted his professional life to the science of fertility preservation and infertility treatment. He is a world-renowned researcher, a gifted medical educator, and a skilled clinician dedicated to his patients. Dr. Oktay was invited to the President's Cancer Panel as an expert on fertility issues of cancer patients and fertility preservation. In attestation to his recognition as a leading clinician-scientist in infertility field, he received a highly competitive multi- million-dollar research grant from the National Institute of Health to study the impact of chemotherapy on fertility of cancer survivors. Furthermore, he was named the co-chair of the American Society of Clinical Oncology Committee for Fertility Preservation Guideline for People with Cancer. He founded and was elected as the first President of the Fertility Preservation Special Interest Group at American Society of Reproductive Medicine.
Post Graduate Studies:
Obstetrics & Gynecology, University of Connecticut Health Science Center, Farmington, CT, USA
Reproductive Endocrinology & Infertility, University of Texas Health Science Center, San Antonio, Texas, USA
Reproductive Biology Fellowship:
ACOG/RCOG Exchange Fellow, Department of Reproductive Biology, Obstetrics & Gynecology, Leeds University School of Medicine/Leeds General Infirmary, Leeds, UK.
Graduate Degree: M.D.
Graduate Degree Institution: Hacettepe University Medical School, Ankara, Turkey
Undergraduate Institution: T.E.D. Ankara College
Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, Dickler M, Robson M, Moy F, Goswami S, Oktay K .Impairment of BRCA1-Related DNA Double-Strand Break Repair Leads to Ovarian Aging in Mice and Humans. Sci Transl Med. 2013 Feb 13;5(172):172ra21. doi: 10.1126/scitranslmed. 3004925. Abstract | Reprint | Full Text
Soleimani R, Heytens E, Darzynkiewicz Z, Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY). 2011 Aug;3(8):782-93.
Soleimani R, Heytens E, Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One. 2011 Apr 29;6(4):e19475.
Oktem O, Buyuk E, Oktay K. Preantral follicle growth is regulated by c-Jun-N-terminal kinase (JNK) pathway. Reprod Sci. 2011 Mar;18(3):269-76. Epub 2010 Oct 19.
Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010 Jan 10;28(2):240-4. Epub 2009 Dec 7.
Roberts JE, Nikolopoulos SN, Oktem O, Giancotti F, Oktay K. Integrin beta-4 signaling plays a key role in mouse embryogenesis. Reprod Sci. 2009 Mar;16(3):286-93. Epub 2008 Dec 15.
Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008 Jun 1;26(16):2630-5.
Oktay K, Buyuk E, Oktem O, Oktay M, Giancotti FG. The c-Jun N-terminal kinase JNK functions upstream of Aurora B to promote entry into mitosis. Cell Cycle. 2008 Feb 15;7(4):533-41.
Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007 Nov 1;67(21):10159-62.